目前国家药典委员会已采用风险评估策略开展中药外源性危害物的限量控制，并逐步开展内源性有毒成分风险控制。很多有毒中药毒性数据缺乏，尤其是多基原中药，化学成分复杂，作“同一药用”的毒理学表现是否一致？这给风险评估的第一步危害识别带来极大挑战。主要存在2个关键问题：一是毒性机制报道较少，信息碎片化，缺乏多种细胞多条通路综合考虑毒性结局；二是品种间成分差异显著，毒性物质基础不明确，缺乏能整体表征中药毒性的“等效毒性成分群”。因此，提出构建基于单细胞转录组学的多基原有毒中药危害识别研究思路及方法，以期为多基原有毒中药风险评估体系的构建提供技术支持。

Currently, Chinese Pharmacopoeia Commission has adopted the risk assessment strategy to carry out the limited control of exogenous hazards of traditional Chinese medicine (TCM) and gradually carried out the risk management of endogenous toxic compounds in TCM. Chemical composition of multi-base source TCM is significantly different and whether the safety of the "same medicinal product" is consistent still lack of scientific explanation. This brings great challenges to hazard identification, which is the first step of risk assessment. There are two key problems in multi-base source toxic TCM. First, the toxicity mechanism is rarely reported and lack of comprehensive consideration of the toxicity in multiple pathways and various cells in condition of information fragmentation. Second, the basis of toxic substances is not clear, and there is a lack of "equivalent toxic composition group" that can characterize the toxicity of TCM as a whole. Therefore, ideas and methods of hazards identification of multi-base source toxic traditional Chinese medicine based on single cell transcriptomics are proposed to establish in this article, in order to provide technical support for the construction of toxic TCM risk assessment system.

R285.53

国家自然科学基金青年项目（82004225）；天津市人才发展特殊支持计划-高层次创新创业团队